AI Article Synopsis
- Schizophrenia is associated with abnormal neurodevelopment, and while growth differentiation factor 11 (GDF-11) might play a role, direct evidence linking it to the disorder is lacking.
- This study involved 87 schizophrenia patients and 76 healthy controls, using the Positive and Negative Syndrome Scale (PANSS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to evaluate symptoms and cognitive function, respectively.
- The findings indicated that GDF-11 levels were significantly lower in schizophrenia patients compared to controls, with negative correlations to symptom severity and positive correlations to specific cognitive functions, suggesting GDF-11 may contribute to both psychopathology and cognitive impairments in schizophrenia.
Article Abstract
Schizophrenia is linked with abnormal neurodevelopment, on which growth differentiation factor 11 (GDF-11) has a great impact. However, a direct evidence linking GDF-11 to the pathophysiology of schizophrenia is still lacking. The current study aimed to investigate the relationship between plasma GDF-11 levels and both psychopathological symptoms and cognitive function in schizophrenia. Eighty-seven schizophrenia patients and 76 healthy controls were enrolled in the present study. The symptomatology of schizophrenia was evaluated using the Positive and Negative Syndrome Scale (PANSS). Cognitive function was assessed by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) including twelve neurocognitive tests in five aspects of cognitive function. Plasma GDF-11 levels were determined by enzyme-linked immunosorbent assay (ELISA). We found that plasma levels of GDF-11 were significantly lower in schizophrenia patients relative to healthy controls. Correlation analysis showed significant negative correlations between the GDF-11 levels and the PANSS total score, the positive symptoms score, the negative symptoms score or the general score. Additionally, positive associations were observed between plasma GDF-11 levels and the visuospatial/constructional, attention, immediate memory, or delayed memory in patients. Partial correlation analysis showed that these correlations were still significant after adjusting for age, gender, education years, body mass index, duration of illness, and age of onset except for the visuospatial/constructional and attention index. Multiple regression analysis revealed that GDF-11 was an independent contributor to the immediate memory, delayed memory and RBANS total score in patients. Collectively, the correlations between plasma GDF-11 and psychopathological and cognitive symptoms suggest that abnormal GDF-11 signaling might contribute to schizophrenic psychopathology and cognitive impairments and GDF-11 could be a potential and promising biomarker for schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750308 | PMC |
| http://dx.doi.org/10.3389/fpsyt.2020.555133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional replacement of myostatin with GDF-11 in the germline of mice.
Skelet Muscle
March 2022
Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.
Background: Myostatin (MSTN) is a transforming growth factor-ß superfamily member that acts as a major regulator of skeletal muscle mass. GDF-11, which is highly related to MSTN, plays multiple roles during embryonic development, including regulating development of the axial skeleton, kidneys, nervous system, and pancreas. As MSTN and GDF-11 share a high degree of amino acid sequence identity, behave virtually identically in cell culture assays, and utilize similar regulatory and signaling components, a critical question is whether their distinct biological functions result from inherent differences in their abilities to interact with specific regulatory and signaling components or whether their distinct biological functions mainly reflect their differing temporal and spatial patterns of expression.
View Article and Find Full Text PDFEffects of Platelet-Rich Plasma on Cellular Populations of the Central Nervous System: The Influence of Donor Age.
Int J Mol Sci
February 2021
Advanced Biological Therapy Unit, Hospital Vithas Vitoria, 01008 Vitoria-Gasteiz, Spain.
Platelet-rich plasma (PRP) is a biologic therapy that promotes healing responses across multiple medical fields, including the central nervous system (CNS). The efficacy of this therapy depends on several factors such as the donor's health status and age. This work aims to prove the effect of PRP on cellular models of the CNS, considering the differences between PRP from young and elderly donors.
View Article and Find Full Text PDFDecreased Plasma Levels of Growth Differentiation Factor 11 in Patients With Schizophrenia: Correlation With Psychopathology and Cognition.
Front Psychiatry
December 2020
Department of Psychosomatic Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Article Synopsis
- Schizophrenia is associated with abnormal neurodevelopment, and while growth differentiation factor 11 (GDF-11) might play a role, direct evidence linking it to the disorder is lacking.
- This study involved 87 schizophrenia patients and 76 healthy controls, using the Positive and Negative Syndrome Scale (PANSS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to evaluate symptoms and cognitive function, respectively.
- The findings indicated that GDF-11 levels were significantly lower in schizophrenia patients compared to controls, with negative correlations to symptom severity and positive correlations to specific cognitive functions, suggesting GDF-11 may contribute to both psychopathology and cognitive impairments in schizophrenia.
Biological strategies for osteoarthritis: from early diagnosis to treatment.
Int Orthop
February 2021
USC Epstein Family Center for Sports Medicine, Keck Medicine of USC, 1520 San Pablo st#2000, Los Angeles, CA, 90033, USA.
Purpose: To provide an updated review of the literature on the use of orthobiologics as a potential treatment option to alleviate symptoms associated with osteoarthritis (OA), slow the progression of the disease, and aid in cartilage regeneration.
Methods: A comprehensive review of the literature was performed to identify basic science and clinical studies examining the role of orthobiologics in the diagnosis and management of osteoarthritis.
Results: Certain molecules (such as interleukin-6 (IL-6), interleukin-8 (IL-8), matrix metalloproteinase (MMPs), cartilage oligomeric matrix protein (COMP), and tumor necrosis factor (TNF), microRNAs, growth differentiation factor 11 (GDF-11)) have been recognized as biomarkers that are implicated in the pathogenesis and progression of degenerative joint disease (DJD).
Aptamer-Based Proteomic Platform Identifies Novel Protein Predictors of Incident Heart Failure and Echocardiographic Traits.
Circ Heart Fail
May 2020
Framingham Heart Study, Framingham, MA (M.N., M.G.L, R.S.V).
Background: We used a large-scale, high-throughput DNA aptamer-based discovery proteomic platform to identify circulating biomarkers of cardiac remodeling and incident heart failure (HF) in community-dwelling individuals.
Methods: We evaluated 1895 FHS (Framingham Heart Study) participants (age 55±10 years, 54% women) who underwent proteomic profiling and echocardiography. Plasma levels of 1305 proteins were related to echocardiographic traits and to incident HF using multivariable regression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!